FDA Priority Review for PADCEV Combo in Bladder Cancer
The U.S. Food and Drug Administration has granted Priority Review to a supplemental Biologics License Application (sBLA) filed by Astellas Pharma Inc. and Pfizer Inc., seeking to expand…
Read More...
Read More...
